TTHI Share Price

Open 1.54 Change Price %
High 1.57 1 Day 0.00 0.00
Low 1.52 1 Week 0.00 0.00
Close 1.52 1 Month 0.00 0.00
Volume 12424 1 Year -0.16 -9.52
52 Week High 1.76
52 Week Low 0.66
TTHI Important Levels
Resistance 2 1.57
Resistance 1 1.55
Pivot 1.54
Support 1 1.49
Support 2 1.47
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
DRYS 1.87 0.00%
ACAS 17.99 0.39%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LINE 0.18 12.50%
ATEA 1.90 11.76%
ATEA 1.90 11.76%
KITD 0.30 11.11%
SGYPU 10.75 10.26%
LPHI 0.24 9.09%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

Transition Therapeutics, Inc. (NASDAQ: TTHI)

TTHI Technical Analysis 4
As on 30th Aug 2016 TTHI Share Price closed @ 1.52 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.37 & Strong Buy for SHORT-TERM with Stoploss of 1.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
TTHI Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TTHI Other Details
Segment EQ
Market Capital 60303716.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.transitiontherapeutics.com
TTHI Address
TTHI
101 College Street
Suite 220
Toronto, ON M5G 1L7
Canada
Phone: 416-260-7770
TTHI Latest News
The Synergy From OPKO's Acquisition of Transition Therapeutics (OPK)   Investopedia   - 15th Sep 16
OPKO Health Completes Acquisition of Transition Therapeutics   Business Wire (press release)   - 31st Aug 16
OPKO Health (OPK) Announces Transition Therapeutics (TTHI) Shareholder ...   StreetInsider.com   - 26th Aug 16
Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401   PR Newswire (press release)   - 18th Apr 16
Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results of ...   PR Newswire (press release)   - 01st Feb 16
Eli Lilly Can Save Transition Therapeutics Inc.   Seeking Alpha   - 30th Dec 15
Transition Therapeutics Inc. (TTHI) Stock | Results of Data Analysis from ...   Warrior Trading News (press release)   - 17th Oct 15
Transition Therapeutics Announces Results of Clinical Study of ELND005 in ...   PR Newswire (press release)   - 24th Jun 15
Transition Therapeutics In-Licenses Phase 2 Drug Candidate from Lilly   PR Newswire (press release)   - 06th May 15
Perrigo Company plc and Transition Therapeutics Modify Development and ...   PR Newswire (press release)   - 28th Feb 14
Interactive Technical Analysis Chart Transition Therapeutics, Inc. ( TTHI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Transition Therapeutics, Inc.
TTHI Business Profile
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with large markets. The Company�s s technologies in development are ELND005 (AZD-103) for the treatment of Alzheimer�s disease and bipolar disorder; TT-401/402 for the treatment of diabetes ,and TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, neuropathic pain, Alzheimer�s disease, traumatic brain injury and intracerebral haemorrhage. The Company has one wholly owned material subsidiary, Waratah Pharmaceuticals Inc. (Waratah), which is engaged in the development and commercialization of its ELND005 (AZD-103); the type II diabetes drug candidate TT-401; and TT-301 and TT-302.